Fred E Cohen bought $1.4M of Intellia Therapeutics (NTLA)
Executed Jan 5, disclosed Jan 7, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Jan 7), the stock returned +12.7% (delay-adjusted); from the execution session (Jan 5), +41.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Fred E Cohen (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Intellia Therapeutics, Inc. (NTLA). Across 1 priced purchase filing, the average 21-session return was +41.7% from execution and +12.7% from disclosure (delay-adjusted; derived). The largest single filing was $1.4M of NTLA (150,000 sh × $9.35, as filed), executed Jan 5.
Healthcare · Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics usi…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→